Estrogen Receptor (ER) PET/CT Imaging in Breast Cancer

Recruiting now

Conditions studied: Breast Cancer, TNBC - Triple-Negative Breast Cancer, Estrogen-receptor-negative Breast Cancer

In brief

18F-Fluoroestradiol (18F-FES) is an estrogen receptor-targeting positron emission tomography tracer with high sensitivity and specificity for the detection of estrogen receptor（ER）-positive tumors . 18F-FES has been used as a predictive biomarker to demonstrate estrogen receptor heterogeneity , to evaluate the pharmacokinetics of estrogen receptor-targeted drugs ， to measure residual estrogen receptors during endocrine therapy and to determine biologically optimal doses of novel estrogen receptor-targeted drugs .This study aimes to explore the efficacy of 18F-FES PET/CT in evaluating the expression levels of ER in primary and metastatic breast cancer patients.

Key facts

Study ID

NCT05541367

Run by

Tongji Hospital

People needed

80

Starts

2021-12-31

Expected to finish

2026-12-31

Last updated by the study team

2022-09-15

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• More than 18 years old
• Patients with pathologically confirmed breast cancer
• Sign the informed consent form

You may not qualify if…

• Pregnant women
• Severe underlying diseases that cannot cooperate with PET examination

Where it is running

• TongjiHospital — Wuhan, Hubei, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.